pbs_code
stringlengths 5
6
| drug
stringclasses 17
values | brand
stringclasses 30
values | formulation
stringclasses 37
values | indication
stringclasses 8
values | treatment_phase
stringclasses 57
values | streamlined_code
stringclasses 33
values | online_application
bool 2
classes | authority_method
stringclasses 2
values | hospital_type
stringclasses 3
values | schedule_code
int64 3.47k
3.47k
| schedule_year
int64 2.02k
2.02k
| schedule_month
stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
14276J | adalimumab | Abrilada | Injection 20 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
14276J | adalimumab | Abrilada | Injection 20 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
9679K | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
9679K | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
9679K | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
9679K | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
9679K | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
9679K | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
9679K | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
9679K | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
9679K | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
9679K | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
9679K | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
9679K | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
9679K | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
9679K | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
9679K | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
9679K | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
11690G | tofacitinib | Xeljanz | Tablet 5 mg | psoriatic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
11690G | tofacitinib | Xeljanz | Tablet 5 mg | psoriatic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
11690G | tofacitinib | Xeljanz | Tablet 5 mg | psoriatic arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
11690G | tofacitinib | Xeljanz | Tablet 5 mg | psoriatic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
12005W | certolizumab pegol | Cimzia | Injection 200 mg in 1 mL single use pre-filled syringe | non-radiographic axial spondyloarthritis | Continuing treatment | null | true | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
12795K | tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilizumab after resolution of the critical shortage of tocilizumab) | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
12795K | tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilzumab after resolution of the critical shortage of tocilizumab) | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
13047Q | infliximab | Remsima SC | Solution for injection 120 mg in 1 mL pre-filled syringe | psoriatic arthritis | Continuing treatment with subcutaneous form or switching from intravenous form to subcutaneous form | null | true | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
12217B | ixekizumab | Taltz | Injection 80 mg in 1 mL single dose pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
12217B | ixekizumab | Taltz | Injection 80 mg in 1 mL single dose pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
12217B | ixekizumab | Taltz | Injection 80 mg in 1 mL single dose pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
12217B | ixekizumab | Taltz | Injection 80 mg in 1 mL single dose pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
10068X | tocilizumab | Actemra | Concentrate for injection 80 mg in 4 mL | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
10068X | tocilizumab | Actemra | Concentrate for injection 80 mg in 4 mL | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
10068X | tocilizumab | Actemra | Concentrate for injection 80 mg in 4 mL | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
10068X | tocilizumab | Actemra | Concentrate for injection 80 mg in 4 mL | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
13304F | tocilizumab | Actemra | Concentrate for injection 80 mg in 4 mL | juvenile idiopathic arthritis | Continuing treatment | 14093 | true | STREAMLINED | Public | 3,471 | 2,024 | NOVEMBER |
9034L | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled syringe | psoriatic arthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
9034L | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled syringe | psoriatic arthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
9034L | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled syringe | psoriatic arthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
9034L | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled syringe | psoriatic arthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
9034L | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled syringe | psoriatic arthritis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
9034L | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled syringe | psoriatic arthritis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
9034L | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled syringe | psoriatic arthritis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
9034L | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled syringe | psoriatic arthritis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
9034L | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled syringe | psoriatic arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
9034L | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled syringe | psoriatic arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
9034L | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled syringe | psoriatic arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
9034L | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled syringe | psoriatic arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
13311N | tocilizumab | Actemra | Concentrate for injection 80 mg in 4 mL | juvenile idiopathic arthritis | Continuing treatment | 14082 | true | STREAMLINED | Private | 3,471 | 2,024 | NOVEMBER |
9615C | etanercept | Enbrel | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
9615C | etanercept | Enbrel | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
9615C | etanercept | Enbrel | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
9615C | etanercept | Enbrel | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
3432P | golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled syringe | psoriatic arthritis | Continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
3432P | golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled syringe | psoriatic arthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
12376J | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled pen | ankylosing spondylitis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
12376J | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled pen | ankylosing spondylitis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
12376J | adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled pen | ankylosing spondylitis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
12376J | adalimumab | Hadlima | Injection 40 mg in 0.4 mL pre-filled pen | ankylosing spondylitis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
12376J | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
12376J | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
12376J | adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
12376J | adalimumab | Hadlima | Injection 40 mg in 0.4 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
12376J | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
12376J | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
12376J | adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
12376J | adalimumab | Hadlima | Injection 40 mg in 0.4 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
12376J | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
12376J | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
12376J | adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
12376J | adalimumab | Hadlima | Injection 40 mg in 0.4 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
9672C | tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | rheumatoid arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
9672C | tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
9672C | tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
9672C | tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
9672C | tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
9672C | tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
11207W | etanercept | Enbrel | Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL | psoriatic arthritis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
11207W | etanercept | Enbrel | Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL | psoriatic arthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
11514B | infliximab | Renflexis | Powder for I.V. infusion 100 mg | psoriatic arthritis | Subsequent continuing treatment | 9188 | true | STREAMLINED | Public | 3,471 | 2,024 | NOVEMBER |
11514B | infliximab | Inflectra | Powder for I.V. infusion 100 mg | psoriatic arthritis | Subsequent continuing treatment | 9188 | true | STREAMLINED | Public | 3,471 | 2,024 | NOVEMBER |
11443G | baricitinib | Olumiant | Tablet 4 mg | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
11443G | baricitinib | Olumiant | Tablet 4 mg | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
11748H | tocilizumab | Actemra Subcutaneous Injection | Injection 162 mg in 0.9 mL single use pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
11748H | tocilizumab | Actemra Subcutaneous Injection | Injection 162 mg in 0.9 mL single use pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
11748H | tocilizumab | Actemra Subcutaneous Injection | Injection 162 mg in 0.9 mL single use pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
11748H | tocilizumab | Actemra Subcutaneous Injection | Injection 162 mg in 0.9 mL single use pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
11202N | etanercept | Brenzys | Injection 50 mg in 1 mL single use auto-injector, 4 | psoriatic arthritis | Subsequent continuing treatment | 9156 | true | STREAMLINED | Any | 3,471 | 2,024 | NOVEMBER |
11489Q | infliximab | Inflectra | Powder for I.V. infusion 100 mg | ankylosing spondylitis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
11489Q | infliximab | Renflexis | Powder for I.V. infusion 100 mg | ankylosing spondylitis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
11489Q | infliximab | Remicade | Powder for I.V. infusion 100 mg | ankylosing spondylitis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
12368Y | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Continuing treatment | 14107 | true | STREAMLINED | Private | 3,471 | 2,024 | NOVEMBER |
12368Y | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Continuing treatment | 14107 | true | STREAMLINED | Private | 3,471 | 2,024 | NOVEMBER |
12368Y | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Continuing treatment | 14107 | true | STREAMLINED | Private | 3,471 | 2,024 | NOVEMBER |
12368Y | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Continuing treatment | 14107 | true | STREAMLINED | Private | 3,471 | 2,024 | NOVEMBER |
13751R | etanercept | Brenzys | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | ankylosing spondylitis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | true | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
13751R | etanercept | Brenzys | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | ankylosing spondylitis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
13751R | etanercept | Brenzys | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | ankylosing spondylitis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | true | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
12209N | ixekizumab | Taltz | Injection 80 mg in 1 mL single dose pre-filled pen | ankylosing spondylitis | Continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
12209N | ixekizumab | Taltz | Injection 80 mg in 1 mL single dose pre-filled pen | ankylosing spondylitis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
13764K | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | true | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |